In addition, this study describes one TCR against the PIK3CAE545K mutant gene product, one of the most frequent PIK3CA mutations that represents 23% of all PIK3CA mutations and is expressed by 2.8% of all patients with advanced cancer [8]. Here, PIK3CA is linked to cancer.